Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Royalty Pharma: Delivering Growth With A Positive Story Ahead
10:02pm, Wednesday, 12'th Feb 2025
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-re
Royalty Pharma Announces R&D Funding Collaboration With Biogen
06:30am, Wednesday, 12'th Feb 2025
Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus Royalty Pharma to provide
Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript
01:40pm, Tuesday, 11'th Feb 2025
Royalty Pharma plc (NASDAQ:RPRX ) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta -
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
10:31am, Tuesday, 11'th Feb 2025
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Stree
Royalty Pharma Reports Q4 and Full Year 2024 Results
07:15am, Tuesday, 11'th Feb 2025
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Port
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
09:00am, Wednesday, 29'th Jan 2025
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
04:15pm, Tuesday, 28'th Jan 2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025
4 Stocks With Growth Potential That Recently Announced Dividend Hikes
09:50am, Wednesday, 22'nd Jan 2025
PLBC, BUSE, LKFN and RPRX recently announced dividend hikes.
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know
10:55am, Monday, 20'th Jan 2025
The mean of analysts' price targets for Royalty Pharma (RPRX) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Royalty Pharma: Key Strategic Updates To Be Priced In
03:49am, Wednesday, 15'th Jan 2025
Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5%
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
10:30am, Monday, 13'th Jan 2025
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, suggesti
Royalty Pharma simplifies corporate structure with $1.1 bln deal
07:31am, Friday, 10'th Jan 2025
Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure.
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
07:30am, Friday, 10'th Jan 2025
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC Significant annual cash savings of greater than $100 million in 2026 growing to over $175 milli
Royalty Pharma Announces Dividend Increase
04:15pm, Thursday, 09'th Jan 2025
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ord
